Literature DB >> 12920209

Biochemical, cytotoxic, and genotoxic effects of ES936, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, in cellular systems.

Donna L Dehn1, David Siegel, Elizabeth Swann, Christopher J Moody, David Ross.   

Abstract

The specific involvement of NAD(P)H:quinone oxidoreductase 1 (NQO1) in the bioactivation of quinone prodrugs has been shown through the use of the inhibitor of NQO1, dicoumarol. Disadvantages of using dicoumarol to inhibit NQO1 include its lack of specificity and its competitive mechanism of inhibition. The concentration of dicoumarol required for inhibition of NQO1 varies according to the substrate under evaluation, which may lead to either false conclusions of the involvement of NQO1 or the alteration of other cellular processes. We have reported previously on the chemical and biochemical properties of ES936, a mechanism-based inhibitor of NQO1 in cell-free systems. In this study, we investigated the effects of ES936 in cellular systems. ES936 (100 nM) inhibits more than 95% of NQO1 activity within 30 min and is stable in complete media at this concentration for a minimum of 2 h. The duration of inhibition is cell line-specific because a new protein must be generated for resumption of activity. ES936 abrogates the toxicity of streptonigrin, with greater effects seen in cell lines expressing higher levels of NQO1. ES936 does not inhibit other cellular reductases, nor does it alter cellular levels of acid-soluble thiols. Some evidence of DNA strand breaks was observed at the concentrations of ES936 required for the inhibition of NQO1 activity. From our studies, we propose the use of ES936 (100 nM) as a mechanism-based inhibitor of NQO1 in cellular systems and for use as a component of the routine activity assay for NQO1.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12920209     DOI: 10.1124/mol.64.3.714

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  12 in total

1.  Akt Phosphorylates NQO1 and Triggers its Degradation, Abolishing Its Antioxidative Activities in Parkinson's Disease.

Authors:  Shilin Luo; Seong Su Kang; Zhi-Hao Wang; Xia Liu; Julia X Day; Zhiping Wu; Junmin Peng; Daxiong Xiang; Wolfdieter Springer; Keqiang Ye
Journal:  J Neurosci       Date:  2019-07-29       Impact factor: 6.167

2.  Role of NAD(P)H:quinone oxidoreductase 1 in clofibrate-mediated hepatoprotection from acetaminophen.

Authors:  Jeffrey S Moffit; Lauren M Aleksunes; Michael J Kardas; Angela L Slitt; Curtis D Klaassen; José E Manautou
Journal:  Toxicology       Date:  2006-11-19       Impact factor: 4.221

3.  Synthesis and evaluation of 3-aryloxymethyl-1,2-dimethylindole-4,7-diones as mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1) activity.

Authors:  Marie A Colucci; Philip Reigan; David Siegel; Aurélie Chilloux; David Ross; Christopher J Moody
Journal:  J Med Chem       Date:  2007-10-18       Impact factor: 7.446

Review 4.  Azoreductases in drug metabolism.

Authors:  Ali Ryan
Journal:  Br J Pharmacol       Date:  2016-09-02       Impact factor: 8.739

5.  Cytotoxicity and genotoxicity of the carcinogen aristolochic acid I (AA-I) in human bladder RT4 cells.

Authors:  Medjda Bellamri; Kyle Brandt; Christina V Brown; Ming-Tsang Wu; Robert J Turesky
Journal:  Arch Toxicol       Date:  2021-05-03       Impact factor: 6.168

6.  Cytotoxic and radiosensitising effects of a novel thioredoxin reductase inhibitor in breast cancer.

Authors:  Nurul A Abdullah; Martyn Inman; Christopher J Moody; Sarah J Storr; Stewart G Martin
Journal:  Invest New Drugs       Date:  2021-03-25       Impact factor: 3.651

7.  Virtual Screening for Potential Phytobioactives as Therapeutic Leads to Inhibit NQO1 for Selective Anticancer Therapy.

Authors:  Bhargav Shreevatsa; Chandan Dharmashekara; Vikas Halasumane Swamy; Meghana V Gowda; Raghu Ram Achar; Vivek Hamse Kameshwar; Rajesh Kumar Thimmulappa; Asad Syed; Abdallah M Elgorban; Salim S Al-Rejaie; Joaquín Ortega-Castro; Juan Frau; Norma Flores-Holguín; Chandan Shivamallu; Shiva Prasad Kollur; Daniel Glossman-Mitnik
Journal:  Molecules       Date:  2021-11-14       Impact factor: 4.411

8.  Upregulation of NAD(P)H:quinone oxidoreductase by radiation potentiates the effect of bioreductive beta-lapachone on cancer cells.

Authors:  Eun K Choi; Kaoru Terai; In-Mi Ji; Yeon H Kook; Kyung H Park; Eun T Oh; Robert J Griffin; Byung U Lim; Jin-Seok Kim; Doo S Lee; David A Boothman; Melissa Loren; Chang W Song; Heon Joo Park
Journal:  Neoplasia       Date:  2007-08       Impact factor: 6.218

9.  Formation and Biological Targets of Quinones: Cytotoxic versus Cytoprotective Effects.

Authors:  Judy L Bolton; Tareisha Dunlap
Journal:  Chem Res Toxicol       Date:  2016-09-29       Impact factor: 3.739

10.  Discovery of a dual inhibitor of NQO1 and GSTP1 for treating glioblastoma.

Authors:  Kecheng Lei; Xiaoxia Gu; Alvaro G Alvarado; Yuhong Du; Shilin Luo; Eun Hee Ahn; Seong Su Kang; Bing Ji; Xia Liu; Hui Mao; Haian Fu; Harley I Kornblum; Lingjing Jin; Hua Li; Keqiang Ye
Journal:  J Hematol Oncol       Date:  2020-10-21       Impact factor: 23.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.